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Background: In recent years, behavioral therapy with comprehensive behavioral inter-
vention for tics (CBIT) has been recognized as an effective and safe treatment in patients 
with Gilles de la Tourette syndrome. In Germany, however, dissemination of CBIT is 
restricted due to a considerable lack of well-trained therapists. The aim of this study 
is to overcome this deficiency by creating a new and sophisticated Internet-delivered 
CBIT (iCBIT) program. With this study, we want to demonstrate that iCBIT is superior to 
Internet-delivered psychoeducation and comparable to face-to-face CBIT.
Method and analysis: This is a multicenter, prospective, randomized, controlled, 
observer-blind clinical trial, which will be conducted at five sites in Germany (ONLINE-
TICS). Over the course of 2  years, 160 adult patients with chronic tic disorders will 
be assigned to one of three treatment arms: iCBIT (n = 72), online psychoeducation 
(n =  72), or face-to-face CBIT (n =  16). All treatments will consist of eighty therapy 
sessions over a period of 10 weeks and will follow the well-established CBIT manual by 
Woods and colleagues. The primary outcome measure will be the change in Yale Global 
Tic Severity Scale (YGTSS) at 1-week posttreatment. Secondary outcome measures 
include YGTSS change at 3 and 6 months, video- and self-ratings of tics as well as 
scales for psychiatric comorbidities assessed at each visit. The primary analysis will 
compare iCBIT to online psychoeducation using a mixed linear model with the YGTSS 
change as dependent variable. Secondary analyses will look at the comparison between 
iCBIT and face-to-face CBIT in a non-inferiority analysis.
discussion: If iCBIT proves to be effective, it would be a considerable contribution 
to close the wide gap in treatment providers for tic disorders not only in Germany but 
also in several other countries, since this Internet-delivered therapy does not require 
the supervision of a therapist. In addition, iCBIT would be a cost-effective and readily 
available treatment alternative that guarantees high quality standard of CBIT.
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introduCtion
Gilles de la Tourette syndrome (TS) is a chronic neuropsychiatric 
disorder of childhood onset characterized by multiple motor and 
vocal tics. While tics are described and diagnosed phenotypi-
cally, there is pathophysiological evidence for an involvement of 
cortico-striato-thalamo-cortical circuits. Tic disorders are com-
mon with a prevalence of 0.4–3.8% (1). The majority of patients 
additionally suffers from comorbidities such as attention deficit 
hyperactivity disorder (ADHD), obsessive-compulsive disorder 
(OCD), depression, anxiety, and self-injurious behavior (2). 
Quality of life is significantly impaired in a substantial number of 
patients not only due to tics and comorbidities but also because 
of ignorance and a lack of information, leading to bullying and 
stigmatization. Even today, it takes on average more than 5 years 
to make the correct diagnosis (3). According to a recent German 
study, TS is a cost-intensive disease that causes high direct and 
in particular high indirect costs (average total annual disease 
specific costs in Germany = €3404) including indirect medical 
costs for productivity loss of €2511 ± 3810 and for absenteeism of 
€260 ± 1184 (4). Thus, TS poses a considerable burden not only 
to patients but also to health-care providers.
For many years, dopamine receptor antagonists have been rec-
ommended as first choice treatment for tics, although these drugs 
are often associated with significant adverse effects. In Germany 
and several other countries, however, only haloperidol is officially 
licensed for the treatment of TS (5). Therefore, a large number of 
other substances (including clonidine, tetrabenazine, dopamine 
agonists, botulinum toxin, and cannabinoids) has been suggested 
for the treatment of tics. However, for most of these medications 
evidence is limited.
Data of two large recently conducted and well-powered rand-
omized controlled trials (RCT) – including more than 100 patients 
each  –  confirmed preliminary results and demonstrated that 
behavioral therapy with Comprehensive Behavioral Intervention 
for Tics (CBIT) is an effective and safe treatment for managing 
the tics of children and adults with TS (6, 7). On average, CBIT 
treatment results in a tic improvement of about 30% [for review, 
see Dutta and Cavanna (8) and Verdellen et al. (9)]. CBIT is a 
short-term behavioral therapy consisting of only eight sessions 
over 10 weeks that includes psychoeducation, habit reversal train-
ing (HRT) with competing-response training (CRT), functional 
analysis, and relaxation training (progressive muscle relaxation). 
The treatment benefit of CBIT was even shown to persist over 
a period of 3 and 6 months (6, 7). Its effectiveness in conjunc-
tion with the lack of side effects are clear benefits of CBIT, and 
are advantages over currently used medications, offering thus a 
competitive alternative for treating tic disorders. Accordingly, in 
the latest guidelines – including those of the European Society for 
the Study of Tourette Syndrome (ESSTS) (5) – behavioral therapy 
with either CBIT or Exposure and Response Prevention Training 
(ERP) (9) is now recommended as the first-line treatment for tic 
disorders (10).
However in Germany and most other European countries, 
this recommendation cannot be implemented, since there is a 
considerable lack of psychotherapists trained in CBIT. Motivated 
by these significant barriers to dissemination, a recent study 
compared the effect of face-to-face to video-delivered CBIT dem-
onstrating comparable efficacy and acceptability (11). However, 
while video-delivered CBIT – compared to face-to-face CBIT – is 
independent of the location, it is still dependent on the avail-
ability of well-trained therapists conducting the video sessions. 
Unfortunately, this is not the case in many European countries, 
including Germany, where therapists trained and experienced in 
CBIT are lacking on a national scale. As of today, there is even no 
therapy manual or patient workbook available for the treatment 
of adult patients with TS in German language.
In other psychiatric conditions such as depression (12, 13) 
and anxiety disorders (14), Internet-delivered self-guided psy-
chotherapy (using cognitive behavioral therapy, interpersonal 
psychotherapy and psychodynamic treatment) has been shown 
to be superior to a control condition and comparably effective 
as face-to-face psychotherapy (15). Due to the simple nature of 
the exercises involved in CBIT, we have reason to assume that 
CBIT is particularly well suited to be delivered via Internet com-
pared to those more complex psychotherapeutic interventions. 
Accordingly, in a recently published meta-analysis on behavior 
therapy for TS, the authors stated that “a major barrier to wider 
implementation of CBIT and HRT is that few therapists are 
trained in their use” and concluded that “broader distribution 
of behavior therapy through increased training or tele-health 
methods is encouraged” (16).
Therefore, the aim of this study will be to develop and test 
a fully self-sufficient Internet-delivered CBIT (iCBIT) for 
adult patients with TS, with no therapist involved in any way 
(ONLINE-TICS). Although interventions via video, Skype, or 
smartphone have been suggested (11, 17, 18) and, in addition, an 
RCT started only recently testing the efficacy of a computerized, 
self-administered version of CBIT (called http://TicHelper.com) 
in 64 children and adolescents with tics (age 8–18 years) (http://
ClinicalTrials.gov Identifier: NCT02413216), to the best of our 
knowledge, so far, there is no iCBIT program available in any lan-
guage for the treatment of tics in adult patients with TS and other 
chronic tic disorders. Since in TS – due to the natural waxing and 
Ethics and dissemination: All institutional review boards approve the protocol. All 
participants will provide informed consent. There are no conflicts of interest. After study 
completion, the results will be published.
Study registration: ClinicalTrials.gov Identifier: NCT02413216.
Keywords: tourette syndrome, tics, comprehensive behavioral intervention for tics, internet-delivered 
comprehensive behavioral intervention for tics, habit reversal training, tele-health program
taBlE 1 | numbers of patients approximately recruited per center.
Center Principal 
investigator
Expected n of 
patients recruited 
for the complete trial
1 Hannover Medical School Müller-Vahl 62
2 Ludwig-Maximilians-
University Munich
Müller 28
3 University of Lübeck Münchau 24
4 University Hospital Aachen Neuner 26
5 University of Dresden Roessner 20
Total 160
n, number.
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waning course of tics – it is difficult to demonstrate efficacy of a 
treatment, only a well-designed and sufficiently powered study 
is suitable to demonstrate efficacy. Therefore, our study will be a 
multicenter, prospective, controlled, randomized, observer-blind 
clinical trial that aims to include 160 patients. ONLINE-TICS will 
be funded by the Federal Ministry of Education and Research 
(BMBF) in Germany (BMBF: 01KG1421). It is designed to 
examine the efficacy of an iCBIT intervention as compared to (1) 
a placebo platform consisting of psychoeducation only – which 
is our primary analysis  –  and (2) a conventional face-to-face 
CBIT intervention  –  which is our secondary analysis. We 
hypothesize that iCBIT (1) is superior to the placebo platform 
and (2) has a comparable effect size to the face-to-face treatment 
arm. Planned participating sites are Hannover Medical School 
(MHH), University of Munich, University of Aachen, University 
of Lübeck, and University of Dresden.
MEtHodS and analySiS
Study Sample
Over the course of 2 years, 160 patients will be enrolled in this 
study. The recruitment will run primarily through the study 
centers’ outpatient clinics. Moreover, further advertisement 
will be carried out by German self-help and advocacy groups, 
newsletters, and annual meetings. Patients who are interested in 
participation will be referred to the study centers, where they will 
be informed about the details of the study and an appointment 
for a screening visit will be made.
During screening, patients will be informed (orally and in 
writing) about clinical assessments and randomized allocation. 
Those patients who will not be randomized to iCBIT during the 
RCT, will have the opportunity of receiving iCBIT after study 
completion (i.e., after their follow-up assessments). There will be 
no financial compensation for the study participation. However, 
travel costs will be reimbursed. Before being enrolled, patients 
will have to provide written consent. We expect a screening rate 
of 280 patients in 2 years, out of which about 240 patients are 
expected to meet the inclusion criteria for this study, out of which 
160 should be willing to participate and will be included. Planned 
recruitment by study site is displayed on Table 1.
Study design
This is a multicenter, prospective, randomized, controlled, 
observer-blind clinical trial on the efficacy of iCBIT in the 
treatment of tics in adult patients with TS or other chronic tic 
disorders. For four of the five planned study sites (except for 
Hanover), a two-armed study design will be used – consisting 
of a placebo-treatment arm (Internet-based psychoeducation) 
and an iCBIT-treatment arm. Only in Hannover (MHH), an 
additional face-to-face CBIT treatment arm will be added. 
Hannover is the only center offering the face-to-face treatment 
due to the lack of well-trained therapists in Germany even in 
centers specializing in TS.
The time from first patient in to last patient out is expected to 
be 33 months consisting of the recruitment phase (24 months) 
plus the treatment phase (10 weeks) plus a follow-up (6 months). 
The drop-out rate is expected to be less than 10%.
This study is registered on ClinicalTrials.gov Identifier: 
NCT02605902.
Eligibility Criteria
The following inclusion criteria were defined:
 – chronic tic disorder or TS according to DSM-5
 – age ≥18 years
 – total tic score of the Yale Global Tic Severity Scale (YGTSS–
TTS) >14 (for patients with TS and YGTSS–TTS >10 for 
patients with other chronic tic disorders)
 – CGI-S >4 at baseline
 – If patients receive additional medical or surgical treatment for 
tics and psychiatric comorbidities, they must be on a stable 
dose for at least 6 weeks before entering the study
 – fluency in German language
 – written informed consent.
Exclusion criteria for this study are:
 – history of schizophrenia or pervasive developmental disorders
 – current diagnosis of substance abuse or dependence
 – primary comorbidities such as OCD, ADHD, depression, 
anxiety disorder, in need of therapy
 – history of behavioral treatment for tics (CBIT, HRT, ERP)
 – secondary tic disorders and other significant neurological and 
psychiatric diseases (such as schizophrenia, thought disorder)
 – no access to Internet or inability to operate a computer
 – participation in any interventional clinical study investigating 
drugs/medical devices 6 weeks prior to study enrollment.
These broad inclusion and exclusion criteria were based on the 
study by Wilhelm et al. (7), and guarantee that a representative 
group of TS treatment-seeking patients will be included, in par-
ticular, patients (1) with moderate or severe tics, (2) with simple 
or complex tics, (3) with or without comorbidities, (4) with or 
without additional drug treatment, (5) with short or long disease 
duration, and (6) of different age groups.
randomization
Potential bias will be minimized by randomized treatment alloca-
tion. The randomization list will be based on permuted blocks 
and is stratified by study site and pre-existing medication for 
the treatment of tics (yes/no). There will be a 1:1 randomization 
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in four/five centers (for reasons explained above), and only in 
Hannover patients will be randomized 1:1:1 until 16 patients 
are randomized to face-to-face CBIT and 1:1 afterward. The 
randomization will be conducted centrally via web randomiza-
tion. Patients will be given a sealed envelope by the investigator 
containing the access code for the therapy platform (or – only at 
the MHH center – information for face-to-face CBIT).
Blinding
The study is observer blind. Although the patients will receive no 
information as to which treatment arm they are assigned to, it can 
be assumed that patients will find out. This will definitely be the 
case in the face-to-face CBIT treatment arm, but will most likely 
happen in the iCBIT – and placebo treatment arms as well, since 
all patients will be informed about the study objectives and the 
contents of the possible treatment arms. Thus, a genuine blinding 
of patients will not be possible. This represents a fundamental 
problem in all studies with psychotherapeutic interventions. 
However, much effort is being put into avoiding the unblinding 
of study physicians:
•	 The examiners involved in the study will only carry out 
assessments. Apart from this, they will not be responsible for 
the treatment of patients during the study period and will not 
answer questions related to the therapy.
•	 Patients will be instructed in writing, neither to talk nor to 
ask questions about the contents of the therapy during the 
study visits. In addition, patients will be explicitly asked by 
the examiner at the beginning of each visit (telephone and 
personal study visits), not to talk about the contents of their 
therapy. Technical as well as content-related assistance related 
to the online platforms will be provided via a central hotline 
located in Hanover through a study staff member who will not 
be involved in assessments.
•	 Despite these precautions, a blinding of the evaluating study 
physicians cannot be guaranteed to 100%. If an investigator 
will be unblinded by a patient, this will be documented directly 
at the respective visit. Whenever possible, the patient will be 
reassessed by an alternative unblinded investigator at this visit 
(if unblinding happened before the completion of this study 
visit) and at all following visits.
•	 The therapist, who will treat patients with face-to-face CBIT 
within this study will not be involved in clinical assessments.
•	 The recording and scoring of videos for tic assessment will not 
take place in the same center (videos will be analyzed centrally 
at the MHH) and only after termination of the study, thus 
blinding of the evaluating physician is guaranteed.
Compliance
In order to ensure that the patients will take active part in the 
Internet-based intervention, several automated checkups are 
integrated into the online platform for two purposes: first, it 
allows to organize and motivate the patients with regard to 
their sessions (missed sessions, time in session, active reminder, 
and more). Second, a direct quantification of the compliance is 
possible after study completion and compliance can be analyzed 
statistically.
To all patients randomized to the placebo platform, an (open, 
uncontrolled) participation in the iCBIT therapy will be offered 
after study completion. However, this will only be possible for 
those patients in the face-to-face CBIT and the placebo treat-
ment arms, who have been compliant before and completed the 
randomized treatment.
internet-delivered CBit
Comprehensive Behavioral Intervention for Tics can be regarded 
as an “extension” of HRT developed for the treatment of patients 
with tics including psychoeducation, tic-awareness training 
(including the awareness of premonitory urges preceding the 
occurrence of the tics), CRT, relaxation training, and functional 
analysis to identify events and situations that influence tic severity 
in order to develop coping strategies to manage these situations. 
HRT, the primary component of CBIT, is based on the premise 
that tics are maintained by response chaining, lack of awareness 
of their occurrence, excessive practice, social reinforcement, 
and tolerance of the tics (19). The core element of HRT, in turn, 
is CRT that aims to introduce a voluntarily performed non-tic 
movement that is physically incompatible with the performance 
of the tic. Thus, the competing response encourages the subject to 
respond to the urge by performing a movement competing with 
the tic. Over time, performance of the competing response breaks 
the cycle between the premonitory urge and the relief following 
the tic.
The iCBIT online platform is being created by the authors 
(Kirsten Müller-Vahl, Nadine Buddensiek, Ewgeni Jakubovski, 
and Cornelia Reichert) and in particular by Kirsten Müller-
Vahl, who is well experienced in all aspects of TS, and Nadine 
Buddensiek, who is an experienced and well-trained psycho-
therapist for CBIT in adults. It is following the manual for face-
to-face CBIT by Woods (20) with respect to both, number and 
content of treatment sessions, distribution of CBIT elements to 
particular treatment sessions, and duration of treatment. Thus, 
the only difference between this conventional and well estab-
lished form of CBIT and iCBIT will be the route of delivery, on 
the one hand via face-to-face and on the other hand via Internet. 
Only very few adaptations have been inevitable due to Internet-
delivery such as more extensive psychoeducation, description of 
CBIT at great length and inclusion of additional contents. For 
example, for better illustration, videos will be included where 
patients as well as an expert clinician (KMV) talk about their 
own experience with both CBIT and TS as well as general aspects 
of TS and contents of CBIT. Additional content will be offered 
in form of a FAQ section, which is meant to provide answers to 
most frequent questions that might arise over the course of the 
program. Comparable to the Woods’ manual for face-to-face 
CBIT, other resources are provided including information about 
the TS, working materials such as “Personal Tic Sheet,” “The Tic 
Symptom Hierarchy Tracker,” “Functional Assessment Form” (to 
help patients identify situations that deteriorate their tics in order 
to develop specific function-based interventions), “Tic Hassle 
Form,” a list of possible competing responses for different tics, 
and a reward program. Working sheets can either be used online 
or can be printed out for use in paper form. A part of the working 
materials can alternatively be used via smartphone app.
5Jakubovski et al. ONLINE-TICS
Frontiers in Psychiatry | www.frontiersin.org June 2016 | Volume 7 | Article 119
In line with the CBIT manual provided by Woods (20), iCBIT 
will consist of eight sessions of which the first two session will 
take 90 min, while the other six sessions will take 60 min. The 
first six sessions will be weekly and the last two sessions will be 
biweekly, totaling to an overall treatment duration of 10 weeks. 
However, iCBIT will allow patients more time flexibility than 
conventional face-to-face CBIT.
Placebo: online Psychoeducation
The control group will consist of psychoeducation only. It will 
match the iCBIT group in terms of the number and duration 
of sessions (eight Internet-delivered sessions over a period of 
10 weeks). Patients in the control group will receive no elements of 
CBIT. Psychoeducation will include additional disorder-specific 
information. A comparable design has been chosen in available 
large RCTs using face-to-face CBIT (6, 7). Due to the well-known 
disadvantages of waiting list designs, we decided against using it 
in our study (21).
Face-to-Face CBit
This additional treatment arm will only be offered in Hanover. 
The face-to-face CBIT therapy will follow the CBIT manual by 
Woods et al. (22). In addition, each face-to-face session will cor-
respond exactly to the iCBIT sessions: treatment will thus consist 
of eight sessions of which the first two sessions will last 90 min 
and the remaining six sessions 60 min (total of 10 weeks).
Booster Sessions
In the period of time from the end of active treatment until the 
last follow-up visit (see below), patients in all treatment arms will 
get the option of receiving booster sessions to refresh the therapy. 
There will be no limitation in terms of number, scope, and dura-
tion of these additional sessions in the Internet-based treatment 
arms. In these sessions, patients will have access to information 
earlier provided in the eight sessions of their treatment module. 
However, no new information or contents will be offered. In 
the face-to-face CBIT group, up to two booster sessions will be 
possible in terms of face-to-face CBIT sessions with the therapist 
[comparable to the CBIT manual by Woods et al. (22) and recent 
studies (7)]. The duration of these sessions will be 60 min each.
online Platform: Minddistrict
The technical implementation of the Internet-based treatment is 
being set in place in cooperation with the Minddistrict company. 
All treatment-related contents for the online modules are being 
developed by the research team at the MHH. In the final stage of 
development, the platform will be reviewed by the authors of the 
original CBIT manual Douglas Woods and Sabine Wilhelm (who 
is a German native speaker). Prior to study begin, the platform 
will be additionally pilot tested by a small group of patients with 
tic disorders to verify its practicability and usability. Feedback 
will be used for further optimization of the platform before study 
launch.
outcome Measures
The primary outcome measure will be the YGTSS–TTS (23) 
1 week after end of treatment. This has also been used in studies 
demonstrating efficacy of face-to-face CBIT (6, 7). Tic severity 
will further be assessed via several secondary outcome measure-
ments using (i) the YGTSS–TTS 3 and 6  months after end of 
treatment, (ii) the Modified Rush Video-Based Tic Rating Scale 
(MRVS) (24), and (iii) the Adult Tic Questionnaire (ATQ), a tic 
self-rating scale, which is parallel in format and content to the 
Parent Tic Questionnaire (25).
The following further secondary outcome measures will be 
included: the Premonitory Urge of Tics Scale (PUTS) (26), Beck 
Depression Inventory (BDI-II) (27), Conners’ Adult ADHD 
Rating Scale (CAARS) (28), Yale-Brown Obsessive-Compulsive 
Scale (Y-BOCS) (29, 30), Beck Anxiety Inventory (BAI) (31), 
Gilles de la Tourette Syndrome-Quality of Life Scale (GTS-QoL) 
(32). In addition, the Clinical Global Impression – Severity Score 
(CGI-S) and the Clinical Global Impression – Improvement Score 
(CGI-I) will be used to measure overall severity of disease and 
improvement at follow-up. An adopted version of the Working 
Alliance Inventory-Short Revised (WAI-SR) will be applied to 
assess the therapeutic alliance (33).
Schedule of assessments
All clinical assessments will be performed at screening, baseline, 
week 5 (during treatment), week 11 (1 week after end of treat-
ment), and 3 and 6  months after end of treatment. Follow-up 
assessments at 3 and 6  months after the end of treatment will 
provide estimates of the durability of treatment effect. Thus, time 
points of assessment in this study are comparable to those in the 
study by Wilhelm et  al. (7), which recently demonstrated that 
face-to-face CBIT is an effective and safe intervention in adults 
with TS. Randomization will be performed at the baseline visit. 
Screening and baseline visits should not be more than 4 weeks 
apart, otherwise the patient will have to be rescreened. A detailed 
assessment schedule is provided on Table  2. At week 17 and 
29 (1.5 and 4.5  months after the end of treatment), telephone 
visits will take place. These additional visits serve the purpose of 
improving compliance in order to keep the drop-out rate as low 
as possible. During these telephone visits there will be no further 
testing.
Sample Size Calculation
The sample size calculation is based on two studies in which the 
efficacy of face-to-face CBIT was compared with face-to-face psy-
choeducation in adult and pediatric patients with TS and chronic 
tic disorders (6, 7). The average YGTSS–TTS improvement across 
both studies was 3.5 (±5.5 SD), when comparing face-to-face 
CBIT to psychoeducation. The basic assumption of our study 
is that iCBIT is as effective as face-to-face CBIT. However, we 
expect a mean difference of 3.0 instead of 3.5 for the sample size 
estimation since only adult patients will be enrolled in this study, 
and a difference of three points is considered relevant enough to 
be detectable.
Under these conditions and with a one-sided type I error of 
2.5%, n = 72 patients per treatment arm are required to reach a 
power of 90%. Therefore, a total of 144 patients will be included 
in the Internet-based treatment arms iCBIT and placebo. 
The expected drop-out rate is considered very low (<10%) 
based on previous studies in our centers and the studies by 
taBlE 2 | assessment schedule.
Study period Screening Baseline treatment: (a) iCBit, (b) placebo,  
(c) Face-to-face CBit
Follow-up visits/booster-treatmenta
Visit 1 1 2 3 4 5
Week −4 −0 0 1 2 3 4 5 6 8 10 11 17 23 29 35
treatment-session 1 2 3 4 5 6 7 8 Frequency individual, for face-to-face  
CBIT: max = 2
General procedures
Written informed consent X
Inclusion/exclusion criteria X
Demographics X
Medical and medication 
history
X
intervention
Randomization X
Complianceb
– Asking for compliance X X X X X X X X X X X X X
– Phone visits X X
– Online check-ups X X X X X X X X
Psychometric assessment
Tics: 
– YGTSS X X X X X X
– ATQ X X X X X
– MRVS X X X X X
Severity of disease: CGI-S X X X X X X
Improvement of disease: CGI-I X X X X
Premonitory urges: PUTS X X X X X
Quality of life: GTS-QoL X X X X X
Mood: BDI-II X X X X X
Anxiety: BAI X X X X X
ADHD: 
– DSM-IV symptom list X
– CAARS X X X X X
OCD: Y-BOCS X X X X X
adverse events
Open question X X X X
therapeutic alliance
WAI-SR X X X X
YGTSS, Yale Global Tic Severity Scale; MRVS, Modified Rush Video-Based Tic Rating Scale; ATQ, Adult Tic Questionnaire; CGI-S, Clinical Global Impression–Severity Score; CGI-I, 
Clinical Global Impression-Improvement Score; PUTS, Premonitory Urge of Tics Scale; GTS-QoL, Gilles de la Tourette Syndrome-Quality of Life Scale; BDI-II, Beck Depression 
Inventory; ADHD, Attention Deficit Hyperactivity Disorder; CAARS, Conner’s Adult ADHD Rating Scale; OCD, Obsessive-Compulsive Disorder; Y-BOCS, Yale-Brown Obsessive-
Compulsive Scale; BAI, Beck Anxiety Inventory, WAI-SR, Working Alliance Inventory-Short Revised.
aBooster-sessions: booster-session are optional. Frequency, scope, and number will vary individually in the iCBIT and placebo groups, in the face-to -face CBIT group up to two 
booster sessions a 60-min between week 11 and 35 are possible.
bCompliance: the compliance of patients in all treatment arms will be assessed during the telephone and in person visits. In the face-to-face CBIT treatment, arm compliance will 
also be determined via regular and full participation in the therapy sessions. In the iCBIT and placebo groups, the participation in the therapy session will be determined automatically 
by the online platform by collecting information on when, how long and where the patients were logged in.
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Wilhelm et al. (7) and Piacentini et al. (6). But even with as low 
as 60–65 patients per treatment arm a power of 84–86% can be 
achieved.
Sample size for the face-to-face CBIT arm in Hannover is fea-
sibility driven. Sixteen patients will be randomized to face-to-face 
CBIT. The study is not powered for this secondary non-inferiority 
analysis.
data analysis
The primary outcome measure (YGTSS–TTS) will be used as a 
continuous variable in the primary statistical analysis. In sec-
ondary analyses, YGTSS–TTS and CGI-I will be used as binary 
covariates for responder analysis: response is defined by a 30% 
decrease (YGTSS–TTS) and an improvement of 1–2 = much or 
very much improved (CGI-I), respectively.
Primary Analysis
The primary analysis will be performed in the intention-to-treat 
population. A mixed linear model will be used with change in 
YGTSS–TTS score (follow-up minus baseline) as the outcome 
variable. Therapy (iCBIT versus placebo), study site, concomitant 
tics medications (yes versus no), YGTSS–TTS baseline score, and 
YGTSS-TTS assessment time point (baseline, week 5, and 1 week 
after end of treatment) as well as an interaction of therapy and time 
point will be included as fixed effects in the model. The patient 
variable will be considered a random effect. The mixed model 
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will be analyzed via PROC MIXED procedure in SAS statistical 
software. The therapeutic effect (iCBIT minus placebo) at week 1 
after the end of treatment and the associated two-sided 95% con-
fidence interval will be obtained from this analysis. Superiority of 
iCBIT will be shown if the upper limit of this confidence interval 
is less than 0.
Various sensitivity analyses are planned (e.g., in a per-protocol 
population, using analysis of covariance and more). In the 
unlikely event that the mixed model will not converge in the 
primary analysis, an analysis of covariance with last observation 
carried forward will be carried out instead.
Secondary Analyses
The key secondary analysis is the comparison of iCBIT to face-to-
face CBIT in terms of YGTSS–TTS change 1-week posttreatment. 
If the primary objective of superiority of iCBIT over Placebo can 
be shown, this key secondary non-inferiority hypothesis can be 
tested in a confirmatory analysis with a one-sided significance 
level of 2.5%. The non-inferiority margin for the mean difference 
(iCBIT versus face-to-face CBIT) will be set to 3. The statistical 
analysis model is in line with the primary analysis described 
above (mixed model).
In further secondary analyses, the mean change from baseline 
to each time point will be tested in MRVS, ATQ, PUTS, GTS-
QoL, WAI-SR, and the psychiatric comorbidity scores by means 
of an analysis of covariance between the treatment groups. The 
analyses will be adjusted for study site and concomitant tic medi-
cations as well as the baseline score of the respective outcome 
variable. Several subgroup analyses are planned as a function 
of pre-stratification-variables: comorbidities, age, gender, and 
duration of disorder. Further analyses investigating interactions 
terms will be conducted in order to assess the robustness of the 
treatment effect across the strata. Proportion of responders will 
be analyzed with logistic regression stratified in line with the 
primary analysis. All secondary endpoints will be analyzed in an 
intention-to-treat population.
Quality assurance and Monitoring
To assure data quality and patients’ safety, regular monitoring 
visits will be carried out. An on-site initiation visit has to be 
performed, before a site is allowed to start recruitment. Periodic 
monitoring visits and source data verification will be done 
according to a risk-adapted approach (34). Close out visits will be 
done at the end of the trial and in case a site will be closed. Project 
managers and monitors will stay in close and regular contact with 
all trial sites.
Quality assurance will be realized by in-house monitoring 
via electronic data capture. On site source data verification will 
be done 100% for the first patient at each center and 20–50% 
reduced risk adapted monitoring afterward. In total, 16 periodic 
monitoring visits are planned (on average, two to three visits/
site). If applicable, monitoring visits will be adapted according 
to recruitment.
Safety
For this study, no safety issues have been identified. Adverse 
events and incidents will be documented via open questions and 
will be analyzed descriptively. Patients can contact the recruiting 
center at any time. If required, however, unblinding will be pos-
sible at any time.
diSCuSSion
Clinical implications
This is the first study examining the efficacy and safety of a 
fully self-sufficient Internet-delivered behavioral therapy using 
CBIT for adult patients with chronic tic disorders that does not 
require the supervision of a therapist (ONLINE-TICS). We will 
carry out a large multicenter, RCT in five different German TS 
centers to compare the efficacy of iCBIT [an online therapy, 
which follows closely the CBIT manual by Woods (20)] to (1) 
an online placebo – containing only psychoeducation – and to (2) 
a conventional and well-established face-to-face CBIT treatment. 
The inclusion of both an online-delivered placebo intervention 
and face-to-face CBIT gives us the unique possibility to investi-
gate not only the superiority of iCBIT over placebo but also the 
non-inferiority compared to face-to-face CBIT.
We expect iCBIT to outperform the psychoeducation online 
platform (placebo) and to show a treatment effect comparable 
to face-to-face therapy. If shown to be effective, iCBIT will have 
several major advantages compared to face-to-face CBIT: (i) 
iCBIT can be delivered to any patient (the only requirement is 
a computer with Internet access), (ii) treatment of patients with 
TS according to latest guidelines will no longer be hampered by 
the lack of therapists trained in CBIT, (iii) iCBIT will shorten 
waiting time, (iv) iCBIT may be a treatment option even for those 
patients who refuse face-to-face psychotherapy due to reasons 
such as effort, costs, difficulties in reaching the therapist’s office 
(for example because of significant tics or a comorbid anxiety 
disorder), and personal career (since for example in Germany 
an appointment as a tenured German civil servant is no longer 
possible after a person has submitted an application for psycho-
therapy to his statutory health insurance), (v) costs for iCBIT 
will be much lower compared to costs for face-to-face CBIT, 
(vi) iCBIT guarantees highest quality standards, and (vii) there 
is evidence that Internet-delivered therapy in general reaches 
other groups of patients (e.g., homemakers, higher-educated 
people, employees, elderly people) as compared to regular face-
to-face therapy (35). Therefore, we can assume that iCBIT will 
be an effective, safe, and cost-effective treatment for a substantial 
number of patients with TS. Thus, if effective, iCBIT will bridge 
a worldwide healthcare gap. In addition, one could think about 
combining elements of both types of treatment, face-to-face 
CBIT and iCBIT in order to improve efficacy (by giving the 
patient the possibility for timely flexible repetitions and the use 
of additional content such as videos, FAQ, and detailed psych-
oeducation) and flexibility (by using alternatively two different 
routes of delivery for CBIT) and as an aid for therapists in their 
work routine.
limitations
All of the treatment arms in our study compare behavioral inter-
ventions, but there is no comparison to medical treatment. Due 
to several reasons, we decided not to use a pharmacotherapy 
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as an active comparator: (i) in Germany, only haloperidol is 
licensed for the treatment of tics, but it is no longer recom-
mended due to significant adverse effects (5), (ii) due to lack 
of controlled clinical trials, the efficacy of those drugs most 
often used at least in Germany (tiapride, risperidone, and 
aripiprazole) is unknown (5) and, therefore, these drugs cannot 
be used as active comparators, (iii) until today there is no trial 
available comparing directly the efficacy of behavioral therapy 
versus pharmacotherapy, and (iv) using one of those drugs 
most often used for the treatment of tics would limit patient 
population, since a substantial number of patients would refuse 
participation.
Our study cannot be considered double-blind, since it will be 
very easy for patients to figure out if they are receiving iCBIT 
or not. This is a common problem that most studies examining 
psychotherapeutic interventions face. Nevertheless, our study 
has a high external validity. Treatment will not take place in 
a clinical setting, but in the homes of the participants. All 
treatment-related exercises will take place in patients’ everyday 
lives. There will be no issue with dissemination, since once 
shown to be effective, iCBIT can be made accessible to anybody 
seeking treatment for tics and will be delivered in the very same 
way, which was shown to be effective. We decided not to use a 
waiting list control designs, since it is well known that these 
trials may overestimate treatment effects. In order to make 
the control group more attractive, patients randomized to the 
control group will receive interesting and helpful information 
about their disorder in an entertaining presentation and, in 
addition, will have the possibility to receive iCBIT after study 
completion.
Our study examines an online treatment that works com-
pletely without the involvement of a therapist. Does that make 
therapists obsolete? Our answer is: definitely not. In our opinion, 
iCBIT offers a solution to overcome the lack of well-trained 
therapists. However, we do not intend to propose a program to 
replace consultation with a qualified medical doctor. An online 
treatment like ours cannot diagnose tics or test the indication 
for treatment; this always has to be done by a mental health 
specialist. Oftentimes, a patient might have several indications 
for treatment of which treatment for tics might be a minor one. 
This diagnostic work always has to be done by an expert. That 
being said, our platform will be a very useful tool to supplement 
therapeutic work in the private practice. The platform could 
assist the patient with regular homework and exercises, while 
a therapist could focus on helping the patient troubleshoot as 
well as work on other issues that the patient might have. This 
would be a timesaving combination for both the patient and the 
therapist.
Conclusion
Our study ONLINE-TICS will test the efficacy of iCBIT  –  an 
online version of the highly effective face-to-face CBIT, which 
is the current first-line treatment for tic disorder. If shown to be 
effective, it will have the potential to bridge a large gap in the 
current health-care system in the treatment of tic disorders in 
Germany.
EtHiCS and diSSEMination
informed Consent and institutional review 
Boards
The study is based on the principles of Good Clinical Practice 
(GCP), according to the Declaration of Helsinki. Patients will 
be given oral and written explanation of the study including its 
potential risks, their right to withdraw consent at any time and the 
details of data protection and confidentiality and sufficient time to 
ask questions. A signed consent form will be obtained. The patient 
information and a copy of the signed consent form will be handed 
to the patient. The data will be monitored by HCTC. All docu-
ments and information will be treated with strict confidentiality.
Each study site will only be able to start data collection once 
the local Institutional Review Boards (IRB) approval is obtained. 
In the case of protocol changes an amendment will be submitted 
to the concerning IRB.
Confidentiality
The information collected in the study, especially the informa-
tion related to the identity of the patient, will be confidential 
and protected by law. The data collected at each study site will be 
stored and analyzed in de-identified form and kept for a period 
of 10 years in a lockable cabinet or password protected computer.
The collected data will be only accessible to the principal 
investigator and study staff of the respective study site as well as 
the monitors.
The Minddistrict company will not have access to any per-
sonal data of the study participants. The necessary login data 
will be provided and managed by the MHH research personal. 
Additionally, the Minddistrict portal will be SSL-encrypted.
Video recordings from all participating study sites will be saved 
on an encrypted cloud offered by the University of Goettingen.
dissemination
After study completion, the results of the primary and second-
ary analyses will be published in international peer-reviewed 
journals.
If shown to be effective the therapy platform will be made 
available to the general public in Germany in an appropriate 
manner. For this purpose, all necessary contractual arrangements 
between the MHH and the company Minddistrict will be clarified 
and defined before the beginning of the study. Currently, all rights 
to the Internet platform iCBIT belong to the MHH represented 
by KMV.
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